Everand Logo

Welcome to Everand!

  • STAT

    Introducing the nominees for best biopharma CEO of 2017. Vote for your favorite!

    The criteria for determining the best biopharma CEO of 2017 was exceptionally high, which makes the nominees on this list all the more exceptional.
    by Adam Feuerstein Dec 11, 2017 2 minutes

    Biopharma has suffered some scares this year in Washington, D.C., and on Wall Street, but from a science perspective, the industry has performed admirably, particularly with big advances in cancer immunotherapy and gene therapy.

    I pored over spreadsheets, dug deep into medical journals, stared at stock charts, and consulted my beloved dog, Bo, to determine this year’s nominees for best biopharma CEO. There were some hard

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
    Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
    Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
    The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.

    Related Books & Audiobooks